@article{fda979472dd14c87aeb1bef89db1305d,
title = "A Phase Ib/II Trial of Trastuzumab-DM1 (T-DM1) with Pertuzumab (P) for Women with HER2-positive, Locally Advanced or Metastatic Breast Cancer (BC) who were Previously Treated with Trastuzumab (T).",
author = "Reshma Mahtani and K. Miller and L. Gianni and F. Andre and V. Dieras and N. Harbeck and J. Huang and T. Shih and Y. Choi and H. Burris",
note = "1012 Background: The HER2-targeted antibody-drug conjugate T-DM1 has shown encouraging efficacy and safety in patients (pts) with heavily pretreated HER2-positive (HER2+) BC. P is the first HER2-directed dimerization inhibitor for treatment of HER2+ BC. T-DM1 and P bind different subdomains of HER2. Combination of P with T or T-DM1 has shown synergistic antitumor activity in HER2+ xenograft models.",
year = "2010",
language = "American English",
volume = "28",
journal = "Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting",
}